Starpharma (ASX:SPL) - CEO, Jackie Fairley
CEO, Jackie Fairley
Source: The Morning Bulletin
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Starpharma’s (SPL) SPL7013 drug shows a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants
  • These strains are classified variants of concern due to their increased transmissibility, increased severity and reduced effectiveness to vaccines
  • Testing was undertaken in the laboratory of virologist Professor Philippe Gallay at The Scripps Research Institute in the US
  • Starpharma will test the Delta and Kappa variants when virus availability permits
  • Starpharma is up 4.5 per cent on the market and shares are trading at $1.63 at 10:41 am AEST

Starpharma’s (SPL) SPL7013 drug has shown a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants.

These strains are classified variants of concern by international public health authorities due to their increased transmissibility, increased severity and reduced effectiveness to current treatments and vaccines.

Testing of SPL7013 was undertaken in the laboratory of virologist Professor Philippe Gallay at The Scripps Research Institute in the US.

The study showed that within 30 seconds to one minute of exposure, SPL7013 achieved more than 99 per cent reduction against the Beta and Gamma variants and more than 99.9 per cent reduction within five minutes against the Alpha variant.

Starpharma will test the Delta and Kappa variants when virus availability permits.

“We are impressed with the rapid and potent virucidal and antiviral activity of SPL7013 and that it is highly active against the Alpha, Beta and Gamma SARS-CoV-2 variants of concern that have emerged and recently dominated the pandemic,” Professor Gallay said.

“It is particularly exciting to see a product with this level of virucidal activity, especially against these variants of concern that are much more transmissible than earlier SARS-CoV-2 strains.”

SPL7013 is a key component of Starpharma’s VIRALEZE nasal spray which works by slowing down the infection of host cells when applied to cells before and after exposure to the virus.

From there, it blocks the interaction between viral surface proteins and human cell receptor proteins.

“We are very pleased to see such potent and rapid virucidal activity of VIRALEZE against multiple SARS-CoV-2 variants of concern, Alpha, Beta and Gamma,” CEO Dr Jackie Fairley commented.

“These variants continue to spread across the globe and challenge efforts to control the COVID-19 pandemic.”

Starpharma was up 4.5 per cent on the market with shares trading at $1.63 at 10:41 am AEST.

SPL by the numbers
More From The Market Herald
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.
The Market Herald Video

" Proteomics International (ASX:PIQ) to raise $8m for Promarker development

Proteomics International (ASX:PIQ) receives firm commitments to raise $8 million to advance marketing, sales and further…
The Market Herald Video

" Paradigm Biopharmaceuticals (ASX:PAR) taps investors for $66m to fund future developments

Paradigm Biopharmaceuticals (ASX:PAR) taps investors for $66 million to fund developments into the 2024 calendar year.